aiwiki.page
English
Health / Diseases & Symptoms / diffuse-midline-glioma

Diffuse midline glioma

Diffuse midline glioma is an aggressive, molecularly defined central nervous system tumor that infiltrates midline structures, most often in children but also in adults.

24 keywords1 linked from3 not yet writtenWritten by AI
Central Nervous…PonsSpinal CordMutationProteinDNAGene ExpressionCerebrospinal Fl…Diffuse mi…

Diffuse midline glioma is an infiltrative glioma arising in midline structures of the central nervous system, particularly the pons, thalamus, and spinal cord. The current diagnostic entity, diffuse midline glioma, H3 K27-altered, is defined by its anatomical location, diffuse growth pattern, and characteristic molecular abnormalities affecting histone regulation. It is classified as CNS WHO grade 4, indicating aggressive biological behavior, even when its microscopic appearance lacks some conventional features of a high-grade tumor.

Classification and terminology

The World Health Organization’s 2021 classification of central nervous system tumors places diffuse midline glioma, H3 K27-altered within the family of pediatric-type diffuse high-grade gliomas. “Pediatric-type” describes a biological grouping rather than an absolute age restriction: these tumors also occur in adults.

The preceding name, diffuse midline glioma, H3 K27M-mutant, emphasized a particular mutation in histone H3. The broader term H3 K27-altered recognizes additional molecular mechanisms that produce a related disruption of histone modification.

The diagnosis requires an integrated interpretation of location, infiltrative growth, tissue findings, and molecular results. An H3 K27 alteration alone does not make every tumor a diffuse midline glioma; tumors outside the appropriate anatomical and pathological setting require separate classification.

Relationship to diffuse intrinsic pontine glioma

Diffuse intrinsic pontine glioma (DIPG) is a clinical and imaging designation for an infiltrative tumor centered in the pons. It overlaps substantially with diffuse midline glioma but is not synonymous with it:

  • Many DIPGs have the molecular features of diffuse midline glioma, H3 K27-altered.
  • Diffuse midline gliomas can arise outside the pons.
  • A diagnosis of DIPG based on imaging alone does not establish a tumor’s molecular classification.

This distinction is important when interpreting older studies, which often grouped patients by imaging findings rather than molecular diagnosis.

Molecular biology

Histones are proteins around which DNA is packaged. Chemical modifications to histones help regulate gene expression.

In many diffuse midline gliomas, a mutation substitutes methionine for lysine at position 27 of histone H3, conventionally called H3 K27M. This alteration disrupts the activity of polycomb repressive complex 2, a protein complex involved in gene silencing. A characteristic consequence is widespread reduction of trimethylation at histone H3 lysine 27, known as H3K27me3.

Other tumors in this category achieve a related molecular effect through mechanisms such as overexpression of EZHIP, a protein that inhibits the same regulatory complex. An EGFR-altered subtype is also recognized. Additional molecular abnormalities contribute to variation between tumors.

These changes affect developmental programs and cellular differentiation rather than simply increasing the rate of cell division. The defining abnormalities are generally acquired within tumor cells; the diagnosis does not ordinarily imply an inherited familial disorder.

Occurrence and clinical features

Diffuse midline glioma occurs most frequently in children, although age distributions differ by anatomical site and molecular subtype. Pontine disease is especially associated with childhood, while thalamic and spinal tumors occur across a wider age range.

Symptoms depend on the structures involved:

  • Pontine tumors may cause abnormal eye movements, facial weakness, difficulty swallowing, slurred speech, limb weakness, and impaired balance.
  • Thalamic tumors may produce weakness, sensory changes, or altered alertness.
  • Spinal tumors may cause progressive weakness, sensory loss, gait disturbance, and bladder or bowel dysfunction.

Tumors that obstruct cerebrospinal fluid circulation can cause hydrocephalus, with symptoms such as headache and vomiting. These manifestations are not specific to diffuse midline glioma and can occur in other neurological conditions.

Diagnosis

Magnetic resonance imaging identifies the tumor’s location, extent, and relationship to surrounding structures. Typical findings include expansion and infiltration of the affected midline structure. Contrast enhancement varies; limited or absent enhancement does not exclude an aggressive tumor.

An integrated molecular diagnosis generally requires tissue obtained through biopsy or, where anatomically feasible, surgery. Assessment may include:

  • Histopathological examination of the tumor’s microscopic appearance.
  • Immunohistochemical testing for mutant H3 K27M protein and loss of H3K27me3.
  • Molecular testing to identify relevant alterations and distinguish related tumor types.
  • DNA methylation profiling in diagnostically difficult cases.

Not all pontine tumors are biopsied. Historically, characteristic imaging and clinical findings were often used to diagnose DIPG without tissue confirmation. Tissue sampling has become more important for molecular classification and research eligibility, but its use depends on location, procedural risk, and the clinical setting.

Treatment

Diffuse midline glioma is difficult to treat because tumor cells infiltrate essential neural tissue rather than forming a sharply separated mass. Complete surgical removal is generally not feasible, especially in the pons. In selected locations, neurosurgical procedures may obtain tissue, relieve obstruction of cerebrospinal fluid flow, or reduce accessible tumor bulk.

Focal radiation therapy is a central component of initial treatment. It can improve neurological symptoms and temporarily control tumor growth, but recurrence or progression is common. Reirradiation is used in selected circumstances.

Conventional chemotherapy has not shown the consistent survival benefit seen in some other brain tumors. Systemic treatment options and their regulatory status depend on the molecular alteration, disease setting, and jurisdiction.

Supportive management addresses neurological disability and treatment-related complications. Corticosteroids may reduce tumor-associated swelling. Rehabilitation, communication and swallowing support, and palliative care address function, symptoms, and quality of life alongside tumor-directed treatment.

Prognosis and research

The prognosis is generally poor, but outcomes vary with anatomical site, age, molecular subtype, and other clinical factors. Historical pediatric DIPG cohorts commonly report median survival of approximately one year after diagnosis. That figure should not be applied uniformly to every molecularly defined diffuse midline glioma, particularly adult and nonpontine tumors.

Research investigates drugs targeting altered cellular signaling and chromatin regulation, improved delivery across the blood–brain barrier, and immune-based treatments. CAR T-cell therapies and other approaches are being evaluated in clinical trials. Important challenges include tumor heterogeneity, limited drug penetration, and the risk that treatment-associated swelling in critical midline structures can impair neurological function. Early evidence of tumor response does not by itself establish durable benefit or improved survival.